UCB Investor

You see, UCB wants to be a world leader when it comes to treating ailments related to the immune and central nervous systems (CNS).


Invests into

Last Funding Type: Post-IPO Equity
Funding Status: IPO
Headquarters: Brussels, Brussels Hoofdstedelijk Gewest, Belgium
Founded Date: 1928-01-01
Investment Stage: Early Stage Venture
Last Funding Date: 2022-05-24
Total Funding: 202213820.0
Employee Number: 5001-10000
Number Of Exists: 3
Acquisitions Number: Made Acquisitions
Estimated Revenue: $1B to $10B
Investors Number: 1
Industry: Biotechnology